BCAL Diagnostics Limited announced it has entered into an agreement with Precion Inc. for the next stage of development of the company's blood based test to detect breast cancer. The Company's US-based and Sydney-based teams will now work directly with Precion's North Carolina laboratories in the development of standardised commercial assays. The assays will be based on the proprietary lipid biomarker signature BCAL identified in the blood samples of early and late-stage breast cancer cohorts.

The parties have signed a Master Services Agreement under which they propose to execute Statements of Work to collaborate in the development of standardised biomarker tests, validate the algorithm required for reporting results and carry out clinical studies in the US. Precion brings together the most advanced technology and an experienced team of scientists with a track record of successfully developing and validating commercial biomarker assays using Mass Spectrometry. The instrumentation utilised by the Precion team will be similar to that currently available in clinical laboratories.

The work will also facilitate similar technology transfer and validation activities being established with laboratories in Sydney, Australia. The execution of this agreement reflects BCAL's ongoing commitment to bring to market novel diagnostic blood tests based on proprietary technology to advance the detection of cancer.